Disease relevance of dimethyl-bis(phenylcarbamoylmethyl)azanium

• The antiarrhythmic agent, N,N-bis(phenylcarbamoylmethyl)dimethylammonium chloride (QX-572) 8 mg/kg body weight produced a decreased conduction time through the atrioventricular node but did not influence intra-atrial or intraventricular conduction [1].
• A second group of 28 patients with acute myocardial infarction also received QX-572 8 mg/kg body wt [2].
• The method was used to determine QX-572 in plasma from 11 patients with various cardiac diseases who received QX-572 8 mg/kg body wt. as an intravenous infusion over 30 min [2].
• For all types of ventricular tachyarrhythmias except rapid idioventricular rhythm there was a lower incidence of arrhythmias in the QX-572 group.. [3].
• The incidence of patients with ventricular tachycardia recorded was significantly lower in the QX-572 group (38%) than in the control group (73%) [3].

High impact information on dimethyl-bis(phenylcarbamoylmethyl)azanium

• The study has provided some preliminary data about the pharmacokinetics of QX-572, but before a detailed analysis can be done data from longer periods of observation is required [2].
• Furthermore, these undesired effects of QX 572 on heart rate were decreased by adrenergic beta blockade in the animals [4].
• It is concluded that QX 572 by some action increased the amount of noradrenaline released from the cardiac sympathetic nerve endings [5].
• It was found that QX 572 increased the heart rate and decreased the blood pressure of the cats during the infusion of the drug [6].
• Randomly it was decided that one group should constitute a control group receiving saline while the second group received QX-572 , MG/KG BODY WEIGHT [7].

Chemical compound and disease context of dimethyl-bis(phenylcarbamoylmethyl)azanium

• Lidocaine and the quarternary ammonium compound QX-572 in acute myocardial infarction. A comparative study [8].

Biological context of dimethyl-bis(phenylcarbamoylmethyl)azanium

• Cardiac output and systemic vascular resistance were unchanged by QX-572 but they were not measured during the infusion when the changes in pressures were most pronounced [7].

Anatomical context of dimethyl-bis(phenylcarbamoylmethyl)azanium

• The positive cardiac chronotropic effects of the antiarrhythmic compound, QX 572, in anaesthetized cats has been shown mainly to be due to a release of catecholamines from sympathetic nerve-endings [4].
• It was found that QX 572 caused an increased heart rate in response to electrical stimulation of the cardiac sympathetic nerves, but this was not due to effects on the CNS, the sympathetic ganglia or the cardiac adrenergic beta-receptors [5].
• Heart rate, pressures in brachial artery and right atrium, cardiac output, stroke volume, and systemic vascular resistance were determined before, during, and up to 30 minutes after completion of placebo or QX-572 [7].

Analytical, diagnostic and therapeutic context of dimethyl-bis(phenylcarbamoylmethyl)azanium

• These variable remained stable in the control group while QX-572 produced an increase in heart rate most pronounced at the end of the infusion period [7].

References